FGFR4 (V550E)
Sign in to save this workspaceFGFR4 · Variant type: point · HGVS: p.V550E
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Upadacitinib | 49.6% | 50.4% | 97.98 |
| 2 | Brigatinib | 31.0% | 69.0% | 82.96 |
| 3 | Pralsetinib | 22.9% | 77.1% | 93.43 |
| 4 | Defactinib | 16.2% | 83.8% | 92.68 |
| 5 | Fedratinib | 15.0% | 85.0% | 96.21 |
| 6 | Tenalisib | 13.7% | 86.3% | 97.98 |
| 7 | Dacomitinib | 13.5% | 86.5% | 97.99 |
| 8 | Palbociclib | 12.9% | 87.1% | 98.75 |
| 9 | Asciminib | 10.6% | 89.4% | 100.00 |
| 10 | Gilteritinib | 10.2% | 89.8% | 88.97 |
| 11 | Ruxolitinib | 9.9% | 90.1% | 98.25 |
| 12 | Repotrectinib | 9.8% | 90.2% | 84.21 |
| 13 | Sunitinib | 8.0% | 92.0% | 91.73 |
| 14 | Erlotinib | 7.6% | 92.4% | 99.75 |
| 15 | Entrectinib | 7.3% | 92.7% | 93.69 |
| 16 | Lapatinib | 5.6% | 94.4% | 99.25 |
| 17 | Neratinib | 5.2% | 94.8% | 93.18 |
| 18 | Idelalisib | 5.2% | 94.8% | 100.00 |
| 19 | Capivasertib | 4.6% | 95.4% | 96.48 |
| 20 | Cobimetinib | 4.4% | 95.6% | 100.00 |
| 21 | Deucravacitinib | 4.3% | 95.7% | 98.99 |
| 22 | Futibatinib | 4.1% | 95.9% | 98.48 |
| 23 | Pacritinib | 3.8% | 96.2% | 88.64 |
| 24 | Vemurafenib | 3.6% | 96.4% | 96.49 |
| 25 | Cabozantinib | 3.6% | 96.4% | 92.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Upadacitinib | 49.6% | — | — |
| Brigatinib | 31.0% | 73.3% | -42.3% |
| Pralsetinib | 22.9% | 64.6% | -41.8% |
| Defactinib | 16.2% | — | — |
| Fedratinib | 15.0% | — | — |
| Tenalisib | 13.7% | 83.9% | -70.2% |
| Dacomitinib | 13.5% | — | — |
| Palbociclib | 12.9% | — | — |
| Asciminib | 10.6% | — | — |
| Gilteritinib | 10.2% | — | — |
| Ruxolitinib | 9.9% | — | — |
| Repotrectinib | 9.8% | — | — |
| Sunitinib | 8.0% | — | — |
| Erlotinib | 7.6% | — | — |
| Entrectinib | 7.3% | — | — |
| Lapatinib | 5.6% | — | — |
| Neratinib | 5.2% | — | — |
| Idelalisib | 5.2% | — | — |
| Capivasertib | 4.6% | — | — |
| Cobimetinib | 4.4% | — | — |
| Deucravacitinib | 4.3% | 92.0% | -87.7% |
| Futibatinib | 4.1% | 97.9% | -93.9% |
| Pacritinib | 3.8% | — | — |
| Vemurafenib | 3.6% | — | — |
| Cabozantinib | 3.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
| carcinoma_breast | Breast | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.9ms